India approves Russia's Sputnik V COVID-19 vaccine

India overtook Brazil to become the nation with the second highest number of infections worldwide after the United States, as it battles a second wave, having given about 105 million doses among a population of 1.4 billion. The RDIF, which is responsible for marketing the vaccine abroad, said the Drug Controller General of India (DCGI) had approved the use of Sputnik V.

Reuters | New Delhi | Updated: 13-04-2021 01:32 IST | Created: 13-04-2021 01:24 IST
India approves Russia's Sputnik V COVID-19 vaccine
Representative Image Image Credit: ANI

India has approved the use of Russian Sputnik V COVID-19 vaccine, the Russian Direct Investment Fund (RDIF) said on Monday, confirming earlier reports of its imminent endorsement. India overtook Brazil to become the nation with the second highest number of infections worldwide after the United States, as it battles a second wave, having given about 105 million doses among a population of 1.4 billion.

The RDIF, which is responsible for marketing the vaccine abroad, said the Drug Controller General of India (DCGI) had approved the use of Sputnik V. "India, the world's 2nd most populous nation, became the 60th country to register #SputnikV after positive results of local Phase 3 clinical study. Sputnik V is now authorized in 60 countries with population of over 3 bln people," a post on the Sputnik V official Twitter account said.

Earlier on Monday, two people familiar with the matter said the panel of the Central Drugs Standard Control Organisation (CDSCO) had recommended the authorisation. The RDIF has signed deals to produce more than 750 million doses of Sputnik V in India with six domestic firms.

India has so far used two vaccines, one developed by AstraZeneca and Oxford University, and the other by domestic firm Bharat Biotech. Sputnik V, developed by Moscow's Gamaleya Institute, has proved 91.6% effective against COVID-19 and has been approved for use in more than 50 countries.

The Indian drugs regulator did not respond to a request for comment on the expert panel's approval of the Russian vaccine. Indian pharmaceutical firm Dr. Reddy's, which is marketing the vaccine in India, said it was awaiting formal word from the authorities.

"Dr. Reddy's and RDIF are working diligently with the Indian regulatory authorities to obtain the approval for Sputnik V. We are fully committed to playing our part in India's fight against COVID," the company said. Shares of Dr Reddy's ended up 5% after the Economic Times newspaper first reported the news.

The firm has helped run a small domestic trial to test the vaccine's safety and ability to generate an immune response. (Additional reporting by Rama Venkat and Shivani Singh in Bengaluru, Polina Ivanova and Vladimir Soldatkin in Moscow; Writing by Sachin Ravikumar; Editing by William Maclean and Angus MacSwan)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Blockchain in Healthcare: Opportunities and challenges

The use of blockchain in healthcare is a relatively new innovation with many of its uses still being explored and related technologies being developed, improved, and scaled. ...

Debate surrounding vaccine passports and development misses bigger picture

... ...

Blockchain vs IOTA: Looking for a better alternative

... ...

For stability, Iraq needs to crack down on corruption

... ...

Videos

Latest News

UN says 155 million people faced severe hunger last year

At least 155 million people faced acute hunger in 2020, including 133,000 who needed urgent food to prevent widespread death from starvation -- and the outlook for 2021 is equally grim or worse, a report by 16 organizations said Wednesday.T...

Scientists model Saturn's interior, explain planet's unique magnetic field

New Johns Hopkins University simulations offer an intriguing look into Saturns interior, suggesting that a thick layer of helium rain influences the planets magnetic field. The models, published in the journal AGU Advances, also indicate th...

Investor group in exclusive talks to acquire Forbes for $650 mln -source

An investor group led by U.S. merchant bank GSVs CEO Michael Moe has entered into exclusive negotiations to acquire business news and information publisher Forbes Media LLC for about 650 million, a person familiar with the matter said on We...

Spain finds 11 cases of variant first identified in India

Spains health minister says the European country has detected 11 cases of the new strain of the coronavirus first identified in India.Minister Carolina Darias says the cases were two separate outbreaks discovered by health officials in rece...

Give Feedback